In end-stage renal disease (ESRD) patients regardless of dialysis modes, i.e. maintenance hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD), potassium (K) homeostasis is regulated primarily via dialysis and extrarenal K regulation in the diverse daily K intake. However, K metabolism has been known to differ greatly between the two main methods of dialysis. Hyperkalemia is a common complication (10-24%) and the most common cause of the death (3-5%) among electrolyte disorders in patients on maintenance HD. On the contrary, hypokalemia (10-36%) is responsible for a rather common complication and independent prognostic factor on CAPD. Although excessive K intake or inadequate dialysis on maintenance HD and poor nutritional K intake on CAPD are accused without doubts upto 50% of ESRD patients as a primary cause of the K-imbalance, i.e. hyperkalemia on HD and hypokalemia on CAPD, other contributory factors including certain medications and unknown causes remain still to be resolved. Accordingly, the effects of medications as another source of K-imbalance on HD with RAS blockades and beta blockers as well as those of conventional and glucose-free dialysates (Icodextrin) for internal K-redistribution on CAPD were evaluated with reviewing the literatures and our data. Furthermore, new developments in the clinical managements of hyperkalemia on HD following the exclusion of pseudohyperkalemia before the initiation of dialysis were suggested, especially, by the comparison of the effects between mono-and dual-therapy with medications for transcellular K shifting in the emergent situation. Also, the intraperitoneal K administration via conventional glucose-containing (2.5%) and glucose-free dialysates (Icodextrin) as a specific route of K-supplementation for hypokalemia on CAPD was examined for its efficiency and the degree of intracellular K shift between these two different types of dialysates.
Introduction
In ESRD patients on renal replacement therapy, K homeostasis is mainly maintained on adequate dialytic K removal and adapted extrarenal K regulation 1) . However, due to the different dialysis modes between HD and CAPD, i.e. the episodic (3-4 times/wk) in HD versus the daily continuous dialysis in CAPD, HD patients do not achieve a steady blood [K] leading to C o r r e s p o n d e n c ea u t h o r : Ho -J u n gKi m,M. D. De p a r t me n to fI n t e r n a lMe d i c i n e ,Ha n y a n g Un i v e r s i t y G u r i Ho s p i t a l , Gu r i , Ko r e a Te l : 0 3 1 ) 5 6 0 -2 2 3 0 F a x: 0 3 1 ) 5 6 7 -5 6 6 6 E -ma i l : k i mh j @h a n y a n g . a c . k r usually highest before dialysis and lowest immediately after dialysis while CAPD patients approach a steady state for it's level, so that wide variations in blood [K] are not present. Excessive dietary K gain before dialysis in HD can temporarily contribute to the development of hyperkalemia but poor dietary K intake in CAPD may lead to hypokalemia. Therefore, hyperkalemia would be more frequent in hemodialysis than in CAPD, especially predialysis stage, and hypokalemia more frequent in CAPD than in HD.
The K imbalance in dialysis patients seems to be primarily related to poor dietary compliance. In fact, too much K intake with poor compliance to diet in interdialytic interval in HD despite adequacy of HD contributes to the high frequency of hyperkalemia (10-24%) responsible for the most common cause of death (3-5%) among electrolyte imbalances, whereas malnutrition with poor K intake in CAPD is a well known factor for the high prevalence of hypokalemia (10-36%) leading to the higher cardiovascular mortality than normokalemic CAPD patients in a recent study 2) . However, besides dietary factors, there are other important factors to be considered among the causes of K imbalance in dialysis patients regardless of dialysis modes, since they are mostly remediable with identi- , and 4) the transcellular K shifts as in healthy subjects.
Hyperkalemia was pointed out as a "potential silent killer" and suggested even one of the leading causes of sudden death in HD patients 5) . In our survey of HD patients during past 10 yrs, 108 out of 548 patients (20%) expired, and its most common causes are cardiovascular disorder (44%) and infection (17%) same as reported in the world literature, but other notable causes included unknown etiologies (22%) and hyperkalemia (6%) 6) . In the admitted patients with severe hyperkalemia, the most common causes of hyperkalemia were related to inadequate dialysis with noncompliance to HD frequency per week (55%) and excessive K intake with noncompliance to dietary regimen (35%) followed by others including medica- increased risk of developing hyperkalemia 11) . Recently, low-dose spironolactone, 25 mg/d 12) , and even the and oral or rectal cation-resins. However, the effect of NaHCO3 for the treatment of hyperkalemia is uncertain and its infusion in varying amount failed to lower serum [K] in ESRD patients 14) , but when combined with insulin with glucose or beta-2 agonists (NAHCO3 alone, -0.13±0.06, p=NS; Salbutamol alone, -0.57± 0.03 mEq/L, p<0.02; NaHCO3 plus salbutamol, -0.96 ± 0.08 mEq/L, p=0.000), their hypokalemic effect were enhanced probably due to the activation of Na-K pump with acute correction of underlying metabolic acidosis in the combined regimen with bicarbonate as dual therapy 15, 16) . Also, other study introduced the efficacious and safe modalities for the acute treatment of hyperkalemia in ESRD patients with the combined regimens as dual therapy, insulin with glucose plus beta 2-agonists 17) . Therefore, once pseudohyperkalemia also present in HD patients as in other general patients is excluded 18) , the temporizing measures of transcellular K shifting regimens can be initiated alone or combined therapy to buy time until hemodialysis can be initiated with the assessment of EKG at the outset as shown in the flow chart ( Fig. 1) 19)
. As a long-term treatment plan of hyperkalemia in HD, the correction of the underlying pathophysiology responsible for hyperkalemia should be started with removal or cautious trials of medications inducing hyperkalemia with balancing the ratio of their benefits and risks in addition to improving the compliance to dialysis and diet. Among other therapeutic regimen for hyperkalemia on the long-term basis, the administration of laxative such as bisacodyl increasing colonic K seretion 20) , and exogenous mineralocorticoid or mineralocorticoid-like substance may provide simple means of reducing interdialytic hyperkalemia in HD 21, 22) .
Hypokalemia on CAPD
In our analysis of serum [K] profile in stable CAPD patients (n=253) 23) , normokalemia (83%) and hypokalemia (16%) were much more frequent than hyperkalemia (1%), being similar to the recent data of Chinese CAPD patients, i.e. normokalemia (80%), hypokalemia (20%), and none in hyperkalemia 2) . The
Chinese data revealed that serum 
